IDEXX Laboratories, Inc.
515.15USD
-5.0600 (-0.97%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.4B | 3.7B | 3.9B | 4.3B | 4.7B | 5.1B |
| Q1 | 836.5M | 900.2M | 964.1M | 998.4M | 1.1B | — |
| Q2 | 860.5M | 943.6M | 1.0B | 1.1B | 1.2B | — |
| Q3 | 841.7M | 915.5M | 975.5M | 1.1B | 1.2B | — |
| Q4 | 828.6M* | 901.6M* | 954.3M* | 1.1B* | 1.2B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 8.03 | 10.06 | 10.67 | 13.08 | 14.83 | 16.74 |
| Q1 | 2.27 | 2.55 | 2.81 | 2.96 | 3.47 | — |
| Q2 | 1.56 | 2.67 | 2.44 | 3.63 | 4.27 | — |
| Q3 | 2.15 | 2.53 | 2.80 | 3.40 | 3.71 | — |
| Q4 | 2.04* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 2.32* |
| 2.60* |
| 3.06* |
| 3.37 |
| — |